Daiwa Securities Group Inc. Sells 200 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Daiwa Securities Group Inc. trimmed its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 10.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,800 shares of the company’s stock after selling 200 shares during the period. Daiwa Securities Group Inc.’s holdings in HealthEquity were worth $147,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HQY. GSA Capital Partners LLP purchased a new stake in HealthEquity during the 3rd quarter valued at $638,000. Vaughan Nelson Investment Management L.P. raised its stake in shares of HealthEquity by 36.7% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after acquiring an additional 226,563 shares during the last quarter. Natixis Advisors LLC boosted its holdings in shares of HealthEquity by 29.8% during the third quarter. Natixis Advisors LLC now owns 209,175 shares of the company’s stock worth $17,122,000 after purchasing an additional 48,009 shares during the period. Oppenheimer Asset Management Inc. grew its stake in shares of HealthEquity by 29.4% in the second quarter. Oppenheimer Asset Management Inc. now owns 64,214 shares of the company’s stock worth $5,535,000 after purchasing an additional 14,573 shares during the last quarter. Finally, Diversify Wealth Management LLC purchased a new position in HealthEquity during the 2nd quarter valued at about $8,182,000. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at HealthEquity

In other news, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the transaction, the director now owns 54,719 shares in the company, valued at $4,540,582.62. The trade was a 13.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Frank Corvino sold 1,039 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the transaction, the director now directly owns 3,784 shares in the company, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,536 shares of company stock valued at $884,517. 2.20% of the stock is owned by insiders.

HealthEquity Stock Performance

Shares of HQY opened at $101.54 on Monday. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. The stock has a market cap of $8.87 billion, a P/E ratio of 84.62, a P/E/G ratio of 1.59 and a beta of 0.52. The business’s 50 day moving average price is $90.16 and its 200-day moving average price is $82.81. HealthEquity, Inc. has a 52 week low of $62.10 and a 52 week high of $105.82.

HealthEquity (NASDAQ:HQY) last released its earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The business had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. Equities research analysts anticipate that HealthEquity, Inc. will post 2.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on HQY shares. Barrington Research reiterated an “outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a research report on Friday, September 20th. Royal Bank of Canada reiterated an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Bank of America lifted their target price on shares of HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, JMP Securities reissued a “market outperform” rating and issued a $105.00 price target on shares of HealthEquity in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.23.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.